A Michigan resident filed a testosterone product lawsuit against drug maker AbbVie Inc., alleging that its drug caused him to develop life-threatening blood clots in his legs.

Plaintiff Robert Taylor took AndroGel from June 2010 until January 2014 and allegedly had several instance of deep vein thrombosis, or DVT. A DVT is a blood clot that forms in body’s largest blood vessels, typically the large veins of the leg. A DVT can cause serious symptoms, but are mostly of concern because they can set the stage for life-threatening medical problems. A DVT can cause pain, swelling, and other problems in the affected leg.

Taylor’s testosterone product lawsuit, and hundreds of other testosterone products lawsuits, allege that drugs like AndroGel increase a person’s risk of DVT and other blood clot-related problems like strokes and heart attacks. In all of these conditions, a blood clot forms within the body. If the clot gets stuck in the blood vessels that feed the heart, lungs, or other sensitive tissues, it can block the supply of oxygen and nutrients to these tissues. When this happens in the brain, it can cause a stroke, in the heart, some types of heart attacks. DVTs are often a precursor to a more serious clot-related problem. In the large veins of the leg, a clot isn’t necessarily causing harm. But the clot can dislodge or break apart, and then migrate through the body to cause heart attacks, strokes, and other clot-related problems. Taylor’s testosterone products lawsuit cites research linking low-T drugs like AndroGel to clot-related problems like DVTs.

Taylor’s testosterone products lawsuit holds that the makers of AndroGel and similar low-T drugs have set out to create demand for their drugs. When the U.S. Food and Drug Administration (FDA) initially approved AndroGel in 1999, drug makers estimated that four to five million men would be most likely make up their entire market. By 2003, this estimate had increased five-fold, to 20 million potential customers.

Among the marketing tools used to achieve this, Taylor’s AndroGel lawsuit alleges, was the “Low-T Quiz” developed by Dr. John Morley. Morley has admitted, according to Taylor’s AndroGel lawsuit, that he “developed” the quiz during a 20-minute bathroom brainstorming session, and that the first draft was literally written on toilet paper. The “Low-T Quiz” including things like “lack of energy” and “falling asleep after dinner” as signs of declining testosterone levels. Morley’s university received a $40,000 grant in exchange for his work on the quiz.

Taylor’s AndroGel lawsuit holds that marketing tools like the “Low-T Quiz” are a bigger part of many men’s decision to begin low-T therapy than actual medical tests. The testosterone product lawsuit cites a 2013 Journal of the American Medical Association article that found more than a quarter of men on Low-T drugs had never actually had their testosterone levels tested.

The Testosterone Product Lawsuit is Robert Taylor v. AbbVie Inc., et al., Case No. 1:14-cv-05232, in the U.S. District Court for the Northern District of Illinois, Eastern Division.